Airway hyperresponsiveness and treatment effectiveness during a one year study of the combination of salmeterol and fluticasone propionate (FP) compared with FP and salmeterol alone in mild to moderate asthma

B. Lundbäck, E. Rönmark, A. C. Jonsson, L. G. Larsson, F. Pètavy, M. H. James (Stockholm, Lulea, Sweden; Uxbridge, United Kingdom)

Source: Annual Congress 2002 - Combination therapies in asthma and COPD
Session: Combination therapies in asthma and COPD
Session type: Poster Discussion
Number: 2397
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
B. Lundbäck, E. Rönmark, A. C. Jonsson, L. G. Larsson, F. Pètavy, M. H. James (Stockholm, Lulea, Sweden; Uxbridge, United Kingdom). Airway hyperresponsiveness and treatment effectiveness during a one year study of the combination of salmeterol and fluticasone propionate (FP) compared with FP and salmeterol alone in mild to moderate asthma. Eur Respir J 2002; 20: Suppl. 38, 2397

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The effects of treatment with fluticasone propionate alone and combination with salmeterol on asthma control and airway inflammation
Source: Eur Respir J 2003; 22: Suppl. 45, 287s
Year: 2003

Treatment effectiveness and exacerbations during one year with seretide compared to fluticasone propionate and salmeterol in mild-to-moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 176s
Year: 2001

Budesonide and formoterol in a single inhaler quickly gains asthma control compared with fluticasone propionate in mild asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 48s
Year: 2001

The effect of fluticasone vs fluticasone plus salmeterol on allergen-induced bronchial inflammation in asthmatic patients. A long-term RCT
Source: Eur Respir J 2004; 24: Suppl. 48, 125s
Year: 2004

Once-daily, high-dose inhaled fluticasone propionate and salmeterol in patients having moderate asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 125s
Year: 2004

Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 292s
Year: 2005

Initial maintenance therapy with fluticasone propionate/ salmeterol combination product provides superior asthma control versus montelukast or fluticasone propionate alone
Source: Eur Respir J 2002; 20: Suppl. 38, 386s
Year: 2002

Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009


Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 386s
Year: 2002

A pilot study comparing tiotropium to salmeterol plus fluticasone in moderate COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

In vivo dose response relation of inhaled fluticasone propionate (FP), adults with bronchial asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 132s
Year: 2004

Achievement of total control of asthma in clinical practice using the combination of inhaled salmeterol and fluticasone propionate
Source: Eur Respir J 2006; 28: Suppl. 50, 616s
Year: 2006

Effect of addition of salmeterol vs doubling the dose of fluticasone propionate on specific airway resistance in children with asthma
Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Year: 2008


Comparison of inhaled ciclesonide, fluticasone propinate and fluticasone propionate + salmeterol in maintaining asthma control
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009

Sustained reduction of bronchial hyperresponsiveness with inhaled fluticasone propionate in mild asthma within three days
Source: Eur Respir J 2002; 20: Suppl. 38, 197s
Year: 2002

Early and sustained benefits of budesonide and formoterol in a single inhaler vs fluticasone in moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 157s
Year: 2001

Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 14s
Year: 2005

Control of airway inflammation is maintained in asthma patients following a 60% reduction in ICS dose with fluticasone propionate/salmeterol (FSC) compared with higher dose fluticasone propionate (FP) alone
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004

Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide - a cost-effectiveness analysis
Source: Eur Respir J 2001; 18: Suppl. 33, 517s
Year: 2001

Effect of the addition of montelukast to inhaled fluticasone propionate on immunopathology in bronchial biopsies from mild to moderate asthmatics
Source: Eur Respir J 2002; 20: Suppl. 38, 388s
Year: 2002